The UK Type 1 Diabetes Research Consortium (UK T1D-RC) was set up in 2015 with major funding from Diabetes UK and the JDRF, to promote, develop and support immunotherapy research in T1D.
Since then, a network of 30 Research Sites has been established throughout the UK to recruit children and adults into clinical trials of new immunotherapy treatments in T1D, monitoring studies and also screening for T1D.
The goal of the UK T1D Research Consortium is to benefit people with T1D or at risk of getting T1D by speeding up the process to finding new treatments to preserve beta cell function in Type 1 Diabetes, “moving towards insulin-free T1D.”
There are 2 main cores to UK T1D, a clinical engagement & training core (CET) led by Prof Colin Dayan from Cardiff University and a mechanistic core of 8 specialist Labs located throughout the UK, led by Tim Tree from Kings College, London.
Be the first to comment